AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32548849 — intervention group
Group type: COMPARATOR
Intervention: Gaviscon placebo (no alginate)
Number of subjects: 30
Study 32548849 — intervention group
Group type: COMPARATOR
Intervention: Viscous slurry (saline mixed with sucralose)
Number of subjects: 30
Study 32548849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate
Number of subjects: 30
Study 32548849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32856608 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium
Number of subjects: 1287
Study 32856608 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium
Number of subjects: 1287
Study 32856608 — intervention group
Group type: EXPERIMENTAL
Intervention: High 25(OH)D
Number of subjects: 1287
Study 32856608 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium and medium 25(OH)D
Number of subjects: 1287
Study 32856608 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium calcium and high 25(OH)D
Number of subjects: 1287
Study 32856608 — intervention group
Group type: EXPERIMENTAL
Intervention: Other classifications of calcium and serum 25(OH)D levels
Number of subjects: 1287
Study 35906581 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based cognitive behavioural therapy (CBT)
Number of subjects: 0
Study 35906581 — intervention group
Group type: COMPARATOR
Intervention: Family-based relaxation therapy
Number of subjects: 0
Study 32665656 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine group (5 mcg ml-1, n=41)
Number of subjects: 82
Study 32665656 — intervention group
Group type: COMPARATOR
Intervention: Non-epinephrine group (n=41)
Number of subjects: 82
Study 33914286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab and briakinumab (combined inhibition of IL-23 and IL-12)
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (JAK inhibitor)
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib and upadacitinib (JAK inhibitors)
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (α4β7 integrin inhibitor)
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrilumab (α4β7-specific)
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab (β7-specific)
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: AJM300 (α4-specific small molecule)
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659 (antibody against endothelial MadCAM-1)
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod (S1PR1 and S1PR5 inhibitor)
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapy
Number of subjects: 0
Study 32570252 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study 34968730 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated group (initially 15 mg QD, escalated to 30 mg QD if lost response)
Number of subjects: 107
Study 34968730 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated group
Number of subjects: 107
Study 34968730 — intervention group
Group type: COMPARATOR
Intervention: Upadacitinib 30 mg
Number of subjects: 107
Study 34968730 — intervention group
Group type: COMPARATOR
Intervention: Upadacitinib 15 mg
Number of subjects: 107
Study 33857664 — intervention group
Group type: EXPERIMENTAL
Intervention: pvl GPi stimulation
Number of subjects: 10
Study 33857664 — intervention group
Group type: EXPERIMENTAL
Intervention: thalamic stimulation (CM-Voi)
Number of subjects: 10
Study 33857664 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 10
Study 33857664 — intervention group
Group type: COMPARATOR
Intervention: baseline
Number of subjects: 10
Study 33857664 — intervention group
Group type: EXPERIMENTAL
Intervention: long-term follow-up
Number of subjects: 10
Study 35582938 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month confirmed disability progression events (score >1.5)
Number of subjects: 8741
Study 35582938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained progression score based on demographic and clinical characteristics
Number of subjects: 8741
Study 35582938 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportions of progression events sustained at 5 years stratified by the score
Number of subjects: 8741
Study 33640659 — intervention group
Group type: EXPERIMENTAL
Intervention: New graduate physiotherapists' experiences and strategies for managing diagnostic uncertainty
Number of subjects: 17
Study 32045067 — intervention group
Group type: COMPARATOR
Intervention: Active Monitoring
Number of subjects: 40
Study 32045067 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 40
Study 34658136 — intervention group
Group type: EXPERIMENTAL
Intervention: Even Up® Hyperpigmentation Regimen; Colorescience, Inc., Carlsbad, CA
Number of subjects: 33
Study 33876196 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline (500 mg/d)
Number of subjects: 52
Study 33876196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 32216227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin, levofloxacin and health education (Group A)
Number of subjects: 171
Study 32216227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin and health education (Group B)
Number of subjects: 171
Study 32216227 — intervention group
Group type: COMPARATOR
Intervention: Health education only (Group C)
Number of subjects: 171
Study 36302173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib (30 mg)
Number of subjects: 34
Study 36302173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg)
Number of subjects: 34
Study 34851253 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine journals (median impact factor 25.0)
Number of subjects: 20
Study 34851253 — intervention group
Group type: COMPARATOR
Intervention: Surgical journals
Number of subjects: 20
Study 34851253 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery publications
Number of subjects: 20
Study 34851253 — intervention group
Group type: COMPARATOR
Intervention: Medicine papers
Number of subjects: 20
Study 33619120 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401
Study 33239018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (received HIV prevention services and enrolled in a 12‐month simulated vaccine efficacy trial using Hepatitis B vaccine)
Number of subjects: 311
Study 33239018 — intervention group
Group type: COMPARATOR
Intervention: Controls (received similar health services but did not enroll in SiVET)
Number of subjects: 311
Study 36154509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD2) (5 mg/ml)
Number of subjects: 124
Study 36154509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD1) (2 mg/ml)
Number of subjects: 124
Study 34010788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years)
Number of subjects: 1067
Study 32271467 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mL PRGF injections
Number of subjects: 50
Study 32271467 — intervention group
Group type: COMPARATOR
Intervention: 1-mL lidocaine injections
Number of subjects: 50
Study 36267577 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) program, 12 weeks, 3-4 sessions per week, 3 sets of 10 repetitions at 60%-80% of 1-repetition maximum
Number of subjects: 49
Study 36267577 — intervention group
Group type: COMPARATOR
Intervention: Usual care including regular physiotherapy and use of orthotics
Number of subjects: 49
Study 35752755 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound guidance (Gp-Usg)
Number of subjects: 96
Study 35752755 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (Gp-Conv)
Number of subjects: 96
Study 32464435 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous posterior tibial nerve stimulation (PTN)
Number of subjects: 50
Study 32464435 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical stimulation (PS)
Number of subjects: 50
Study 32464435 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PTN and PS)
Number of subjects: 50
Study 36263928 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/ml (Gla-300)
Number of subjects: 343
Study 36263928 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec 100 U/ml (IDeg-100)
Number of subjects: 343
Study 32892235 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST)
Number of subjects: 98
Study 32609756 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence clubs (AC) intervention
Number of subjects: 1060
Study 32609756 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1060
Study 35943370 — intervention group
Group type: EXPERIMENTAL
Intervention: 10ml aloe vera mouth wash (99.6% (w/v))
Number of subjects: 30
Study 35943370 — intervention group
Group type: COMPARATOR
Intervention: 0.2% 10ml chlorhexidine mouth wash
Number of subjects: 30
Study 34580499 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care for 3 hours after birth
Number of subjects: 112
Study 34580499 — intervention group
Group type: COMPARATOR
Intervention: Standard postpartum procedure
Number of subjects: 112
Study 32738887 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34637858 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.0125 mg.kg-1)
Number of subjects: 50
Study 34637858 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo solution)
Number of subjects: 50
Study 33562394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (20,000 IU of VD3/week for 24 weeks)
Number of subjects: 330
Study 33562394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 35623017 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude journaling
Number of subjects: 132
Study 35623017 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude reflection
Number of subjects: 132
Study 35623017 — intervention group
Group type: EXPERIMENTAL
Intervention: App prompted reflection
Number of subjects: 132
Study 35623017 — intervention group
Group type: COMPARATOR
Intervention: Activity-matched control group
Number of subjects: 132
Study 34549720 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC oxygen therapy
Number of subjects: 178
Study 34549720 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula oxygen therapy
Number of subjects: 178
Study 33871015 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily motivational text messages
Number of subjects: 93
Study 33871015 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational messages
Number of subjects: 93
Study 33871015 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback messages
Number of subjects: 93
Study 32439224 — intervention group
Group type: EXPERIMENTAL
Intervention: propylene glycol (PG) + Lentulo
Number of subjects: 60
Study 32439224 — intervention group
Group type: COMPARATOR
Intervention: distilled water (DW) + Lentulo
Number of subjects: 60
Study 34470064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled Lighting (CL)
Number of subjects: 147
Study 34470064 — intervention group
Group type: COMPARATOR
Intervention: Continuous Near Darkness (CND)
Number of subjects: 147
Study 32017373 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal orientation of the intraocular lens optic-haptic junctions at 180°
Number of subjects: 201
Study 32017373 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (no manipulation of IOL orientation)
Number of subjects: 201
Study 34558847 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (APAP) 650 mg twice per day (1.3 g/day) for 4 days, followed by 650 mg on the morning of day 5.
Number of subjects: 24
Study 34558847 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without cirrhosis)
Number of subjects: 24
Study 33086144 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation with mindfulness (BAM)
Number of subjects: 231
Study 33086144 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 231
Study 36135595 — intervention group
Group type: COMPARATOR
Intervention: PR (Periapical Radiography)
Number of subjects: 52
Study 36135595 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT (Cone Beam Computed Tomography)
Number of subjects: 52
Study 32299512 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychiatric treatment (10 sessions over 4 months)
Number of subjects: 80
Study 32299512 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study 34076401 — intervention group
Group type: EXPERIMENTAL
Intervention: ACU‐D1 (27 subjects)
Number of subjects: 40
Study 34076401 — intervention group
Group type: COMPARATOR
Intervention: Comparator vehicle (13 subjects)
Number of subjects: 40
Study 34114154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Residue Diet (LRD)
Number of subjects: 195
Study 34114154 — intervention group
Group type: COMPARATOR
Intervention: Clear Liquid Diet (CLD)
Number of subjects: 195
Study 34907265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (2 mg/0.05 ml) administered via 3 intravitreal injections at approximately 30-day intervals
Number of subjects: 24
Study 34907265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 24
Study 33252936 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoring intervention
Number of subjects: 100
Study 33252936 — intervention group
Group type: COMPARATOR
Intervention: Dampening intervention
Number of subjects: 100
Study 33169444 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% NMES
Number of subjects: 32
Study 33169444 — intervention group
Group type: EXPERIMENTAL
Intervention: 55% NMES
Number of subjects: 32
Study 33169444 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% NMES
Number of subjects: 32
Study 33169444 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-stimulation
Number of subjects: 32
Study 36315274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysate sodium (135 mmol/L)
Number of subjects: 15
Study 36315274 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate sodium (138 mmol/L)
Number of subjects: 15
Study 34398950 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic splanchnic nerve block with absolute alcohol
Number of subjects: 96
Study 34398950 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 96
Study 35099566 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal‐backed total knee arthroplasty (MBT)
Number of subjects: 115
Study 35099566 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐polyethylene total knee arthroplasty (APT)
Number of subjects: 115
Study 35099566 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously migrating TKAs (9 implants)
Number of subjects: 115
Study 32683594 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFire® FilmArray® meningitis/encephalitis (FA‐ME) panel
Number of subjects: 142
Study 32683594 — intervention group
Group type: COMPARATOR
Intervention: Separate molecular CSF microbiological tests (control group)
Number of subjects: 142
Study 36241349 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cycle (NC)
Number of subjects: 888
Study 36241349 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement treatment (HT)
Number of subjects: 888
Study 34157994 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (self-monitoring of daily steps plus counseling)
Number of subjects: 188
Study 34157994 — intervention group
Group type: EXPERIMENTAL
Intervention: Single component intervention (self-monitoring of steps only)
Number of subjects: 188
Study 34157994 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 188
Study 32340904 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-rich supplement in combination with nutrition and physical exercise program
Number of subjects: 52
Study 32340904 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 52
Study 34968819 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oxytocin infusion following amniotomy
Number of subjects: 240
Study 34968819 — intervention group
Group type: COMPARATOR
Intervention: Delayed oxytocin infusion following amniotomy
Number of subjects: 240
Study 33346081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity shave margins (CSMs) resected
Number of subjects: 109
Study 33346081 — intervention group
Group type: COMPARATOR
Intervention: No cavity shave margins (no-shave)
Number of subjects: 109
Study 33346081 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of DCIS
Number of subjects: 109
Study 34452964 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 90
Study 34452964 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 90
Study 32646638 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB prescribed at discharge
Number of subjects: 696
Study 32646638 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker prescribed at discharge
Number of subjects: 696
Study 32646638 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA prescribed at discharge
Number of subjects: 696
Study 32646638 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient clinic and HF disease management program review within 30 days
Number of subjects: 696
Study 32646638 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy prescribed
Number of subjects: 696
Study 32646638 — intervention group
Group type: EXPERIMENTAL
Intervention: Excellent guideline adherence score
Number of subjects: 696
Study 35360482 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50
Study 35360482 — intervention group
Group type: COMPARATOR
Intervention: Longdan Xiegan decoction
Number of subjects: 50
Study 32375905 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg d-cycloserine (DCS)
Number of subjects: 40
Study 32375905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35560310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa-based flavanols (FLV; 900 mg/d)
Number of subjects: 11
Study 33900204 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention for CVD management including medication and CVD risk data from EHR, personalized risk score estimation, goal setting, self-monitoring, social forum, heart health messages.
Number of subjects: 486
Study 33900204 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention for CVD management (high users).
Number of subjects: 486
Study 33900204 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention for CVD management (high log-in frequency).
Number of subjects: 486
Study 32417239 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic hemorrhagic transformation (HT)
Number of subjects: 448
Study 32417239 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic hemorrhagic transformation (HT)
Number of subjects: 448
Study 35927020 — intervention group
Group type: EXPERIMENTAL
Intervention: Disadvantage indices for vaccine allocation
Number of subjects: 2003
Study 35927020 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical anchor indicating expert recommendations
Number of subjects: 2003
Study 35927020 — intervention group
Group type: COMPARATOR
Intervention: Randomised condition without numerical anchor
Number of subjects: 2003
Study 32643966 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 24081
Study 32643966 — intervention group
Group type: COMPARATOR
Intervention: Other nonsteroidal anti-inflammatory drugs
Number of subjects: 24081
Study 34888861 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-Enhanced HNC (TE-HNC)
Number of subjects: 101
Study 34888861 — intervention group
Group type: COMPARATOR
Intervention: Helping the Noncompliant Child (HNC)
Number of subjects: 101
Study 32679040 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care
Number of subjects: 188
Study 32679040 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 188
Study 34773725 — intervention group
Group type: EXPERIMENTAL
Intervention: 755-nm picosecond laser
Number of subjects: 20
Study 34773725 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm picosecond laser
Number of subjects: 20
Study 33058366 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nursing based on risk prevention
Number of subjects: 156
Study 33058366 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 156
Study 34156915 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot shower application
Number of subjects: 104
Study 34156915 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hot shower)
Number of subjects: 104
Study 34023008 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 1683
Study 34023008 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 1683
Study 34023008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1683
Study 36380117 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer League (SL) intervention with 778 men attending soccer three times weekly for 6 months (72 sessions; 94% uptake, 45.5% weekly attendance rate) combined with an HIV/substance use cognitive-behavioral intervention.
Number of subjects: 1193
Study 36380117 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CC) with 415 men receiving educational materials and referrals at 3 month intervals.
Number of subjects: 1193
Study 32618627 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group (audiovisual distraction with a VR headset during induction)
Number of subjects: 71
Study 32618627 — intervention group
Group type: COMPARATOR
Intervention: No VR group (no audiovisual distraction)
Number of subjects: 71
Study 32618627 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 71
Study 32409944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) treatment
Number of subjects: 61